Baxter International is selling its vaccine business to Pfizer for $635 million as it prepares to split into two companies.
Pfizer's second-quarter earnings plunged 79% from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.
The rumblings that corporate tax reform will close favorable loopholes for pharmaceutical and biotechnology companies are getting louder, fueling a rush of high-dollar cross-border deals.
Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.
With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from Pfizer to create the world's largest pharmaceutical company.
With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from rival Pfizer to create the world's largest pharmaceutical company. The record-setting offer is just one of a slew of mega-deals this year in the pharmaceutical and...
British drug maker AstraZeneca rejected Monday what its New York-based rival Pfizer called over the weekend its "final" takeover offer.
Several hundred women are suing Pfizer in federal court, alleging the company knew that women taking Lipitor faced an increased risk of developing Type 2 diabetes and that Pfizer's warning label did not clearly describe that risk.
Pharmaceutical company AstraZeneca on Friday flatly rejected drug maker Pfizer's sweetened takeover bid — worth $106 billion — just hours after it was levelled, describing it as inadequate.
Shares in Anglo-Swedish drugmaker AstraZeneca jumped 15% on Monday after U.S. pharmaceutical company Pfizer said it offered to buy the company for around $100 billion.
A robust sales year for three of Novartis' medications allowed the firm to pass reeling Pfizer for the top spot on Modern Healthcare's annual list of largest publicly traded pharmaceutical companies.
Two drugs from Pfizer and Eli Lilly & Co. that employ a new therapeutic approach showed promise in slowing the course of breast cancer, according to early-stage research released on Sunday.